Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients
- 1 December 1998
- journal article
- Published by Elsevier BV in Kidney International
- Vol. 54, S135-S139
- https://doi.org/10.1046/j.1523-1755.1998.06827.x
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Effects of low-dose nifedipine on urinary protein excretion rate in patients with renal diseaseNephrology Dialysis Transplantation, 1998
- Efficacy and Tolerability of Losartan in Hypertensive Patients With Renal ImpairmentHypertension, 1998
- Association of chronic kidney graft failure with recipient blood pressureKidney International, 1998
- Angiotensin II blockade decreases TGF-β1 and matrix proteins in cyclosporine nephropathyKidney International, 1997
- The pharmacokinetics of losartan in renal insufficiencyJournal Of Hypertension, 1995
- Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipne ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertensionThe American Journal of Cardiology, 1995
- Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells.JCI Insight, 1994
- Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusionKidney International, 1993
- Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplantsKidney International, 1993
- Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensivesKidney International, 1990